All In Biotech

Drug Trial Radar · NCT03129490

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Atrial Fibrillation (DANNOAC-AF).

Last checked: Nov 19, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 11,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

11,000

Planned (sponsor's estimate)

Start

Apr 1, 2023

Primary completion

Oct 30, 2027

Study completion Oct 30, 2027

Sponsor

Lead sponsor
Herlev and Gentofte HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 26, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-AF study is a nationwide cluster randomized cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in atrial fibrillation and atrial flutter across Danish hospitals and cardiology clinics.

Conditions

  • Atrial Fibrillation
  • Atrial Flutter

Interventions

  • Dabigatran Etexilate Oral CapsuleDrug

    After cluster randomization, the cluster will use dabigatran to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

  • Rivaroxaban Oral TabletDrug

    After cluster randomization, the cluster will use rivaroxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

  • Edoxaban Oral TabletDrug

    After cluster randomization, the cluster will use edoxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

  • Apixaban Oral TabletDrug

    After cluster randomization, the cluster will use apixaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary efficacy outcome: A composite endpoint of stroke, myocardial infarction, thromboembolic event or all-cause death.Time frame: 2 years.

Locations

38 sites in 1 country. Site status is shown where the registry gives one.

  • Hjerteklinik Nordjylland

    Aalborg, Denmark

  • Aarhus University Hospital

    Aarhus, Denmark

  • Hjertelægerne i Ballerup

    Ballerup Municipality, Denmark

  • Hjertelæge Christian Lange

    Copenhagen, Denmark

  • Bispebjerg Hospital - Department of Geriatrics

    Copenhagen, Denmark

  • Hjerteklinikken Amaliegade

    Copenhagen, Denmark

  • Hjerteklinikken ved Speciallæge Anders Galløe

    Copenhagen, Denmark

  • Bispebjerg Hospital - Department of Neurology

    Copenhagen NV, Denmark

  • Hjerteklinik Østerbro I/S

    Copenhagen Ø, Denmark

  • Rigshospitalet

    Copenhagen Ø, Denmark

  • Amager Hospital

    Copenhagen S, Denmark

  • Esbjerg Hospital

    Esbjerg, Denmark

  • Bispebjerg and Frederiksberg Hospital - Department of Cardiology

    Frederiksberg, Denmark

  • Frederiksberg Hjerteklinik

    Frederiksberg, Denmark

  • Nordsjællands Hospital - Frederiksund

    Frederikssund, Denmark

  • Gentofte Hospital

    Gentofte Municipality, Denmark

  • Glostrup Hospital - Department of Emergency Medicine

    Glostrup Municipality, Denmark

  • Glostrup Hospital - Department of Medicine / Cardiology

    Glostrup Municipality, Denmark

  • Glostrup Hospital - Department of Neurology

    Glostrup Municipality, Denmark

  • Herlev-Gentofte Hospital - Department of Medicine

    Herlev, Denmark

  • Hjertelægerne i Hillerød

    Hillerød, Denmark

  • Nordsjællands Hospital - Hillerød

    Hillerød, Denmark

  • Hjørring Hospital

    Hjørring, Denmark

  • Holbæk Hospital

    Holbæk, Denmark

  • Speciallæge Michael Dilou Jacobsen

    Holte, Denmark

  • Hvidovre Hospital

    Hvidovre, Denmark

  • Næstved Hospital

    Næstved, Denmark

  • Odense University Hospital - Department of Cardiology

    Odense, Denmark

  • Odense University Hospital - Department of Emergency Medicine

    Odense, Denmark

  • Odense University Hospital - Department of Geriatrics

    Odense, Denmark

  • Odense University Hospital - Department of Neurology

    Odense, Denmark

  • Bornholms Hospital

    Rønne, Denmark

  • Zealand University Hospital - Department of Neurology

    Roskilde, Denmark

  • Zealand University Hospital Roskilde - Department of Cardiology

    Roskilde, Denmark

  • Slagelse Hospital

    Slagelse, Denmark

  • Odense University Hospital Svendborg

    Svendborg, Denmark

  • Klinik Hjertesund

    Taastrup, Denmark

  • Vejle Hospital

    Vejle, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.